Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex - PubMed (original) (raw)
. 1996 Jul 25;382(6589):325-31.
doi: 10.1038/382325a0.
Affiliations
- PMID: 8684460
- DOI: 10.1038/382325a0
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex
A A Russo et al. Nature. 1996.
Abstract
The crystal structure of the human p27Kip1 kinase inhibitory domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determined at 2.3 angstrom. p27Kip1 binds the complex as an extended structure interacting with both cyclin A and Cdk2. On cyclin A, it binds in a groove formed by conserved cyclin box residues. On Cdk2, it binds and rearranges the amino-terminal lobe and also inserts into the catalytic cleft, mimicking ATP.
Comment in
- Under arrest at atomic resolution.
Morgan DO. Morgan DO. Nature. 1996 Jul 25;382(6589):295-6. doi: 10.1038/382295a0. Nature. 1996. PMID: 8684452 No abstract available.
Similar articles
- Under arrest at atomic resolution.
Morgan DO. Morgan DO. Nature. 1996 Jul 25;382(6589):295-6. doi: 10.1038/382295a0. Nature. 1996. PMID: 8684452 No abstract available. - Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G, Hunter T, Ruoslahti E. Orend G, et al. Oncogene. 1998 May;16(20):2575-83. doi: 10.1038/sj.onc.1201791. Oncogene. 1998. PMID: 9632134 - Identification of cdk2 binding sites on the p27Kip1 cyclin-dependent kinase inhibitor.
Kwon TK, Nordin AA. Kwon TK, et al. Oncogene. 1998 Feb 12;16(6):755-62. doi: 10.1038/sj.onc.1201586. Oncogene. 1998. PMID: 9488039 - Structuring cell-cycle biology.
Levine K, Cross FR. Levine K, et al. Structure. 1995 Nov 15;3(11):1131-4. doi: 10.1016/s0969-2126(01)00248-9. Structure. 1995. PMID: 8591023 Review. - X-ray crystallographic studies of CDK2, a basis for cyclin-dependent kinase inhibitor design in anti-cancer drug research.
Furet P. Furet P. Curr Med Chem Anticancer Agents. 2003 Jan;3(1):15-23. doi: 10.2174/1568011033353515. Curr Med Chem Anticancer Agents. 2003. PMID: 12678911 Review.
Cited by
- Rate constants and mechanisms of intrinsically disordered proteins binding to structured targets.
Zhou HX, Pang X, Lu C. Zhou HX, et al. Phys Chem Chem Phys. 2012 Aug 14;14(30):10466-76. doi: 10.1039/c2cp41196b. Epub 2012 Jun 28. Phys Chem Chem Phys. 2012. PMID: 22744607 Free PMC article. Review. - Targeting the cyclin-binding groove site to inhibit the catalytic activity of CDK2/cyclin A complex using p27(KIP1)-derived peptidomimetic inhibitors.
Karthiga A, Tripathi SK, Shanmugam R, Suryanarayanan V, Singh SK. Karthiga A, et al. J Chem Biol. 2014 Sep 18;8(1):11-24. doi: 10.1007/s12154-014-0124-y. eCollection 2015 Jan. J Chem Biol. 2014. PMID: 25584078 Free PMC article. - An integrated view of cyclin E function and regulation.
Siu KT, Rosner MR, Minella AC. Siu KT, et al. Cell Cycle. 2012 Jan 1;11(1):57-64. doi: 10.4161/cc.11.1.18775. Epub 2012 Jan 1. Cell Cycle. 2012. PMID: 22186781 Free PMC article. - Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity.
Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, Young SN, Lucet IS, Norton RS, Nicola NA. Babon JJ, et al. Immunity. 2012 Feb 24;36(2):239-50. doi: 10.1016/j.immuni.2011.12.015. Immunity. 2012. PMID: 22342841 Free PMC article. - Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis.
Martins CP, Berns A. Martins CP, et al. EMBO J. 2002 Jul 15;21(14):3739-48. doi: 10.1093/emboj/cdf364. EMBO J. 2002. PMID: 12110586 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases